uniQure (NASDAQ:QURE) Trading Up 5.8% on Analyst Upgrade

uniQure (NASDAQ:QURE) traded up 5.8% on Friday after Mizuho raised their price target on the stock from $7.00 to $20.00. Mizuho currently has a neutral rating on the stock. uniQure traded as high as $16.38 and last traded at $16.36. 193,269 shares were traded during trading, a decline of 88% from the average session volume of 1,651,960 shares. The stock had previously closed at $15.47.

Other equities analysts also recently issued reports about the stock. StockNews.com upgraded shares of uniQure to a “sell” rating in a report on Wednesday, December 11th. Wells Fargo & Company raised shares of uniQure from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 10th. Guggenheim reiterated a “buy” rating on shares of uniQure in a report on Wednesday, December 11th. Cantor Fitzgerald raised their price target on uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a research note on Tuesday, December 10th. Finally, Raymond James raised shares of uniQure from an “outperform” rating to a “strong-buy” rating and upped their price target for the stock from $20.00 to $52.00 in a research report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, uniQure presently has an average rating of “Moderate Buy” and a consensus target price of $33.88.

Insider Buying and Selling

In related news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction on Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the sale, the chief executive officer now directly owns 597,915 shares in the company, valued at $4,562,091.45. This trade represents a 0.57 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.74% of the stock is owned by insiders.

Institutional Investors Weigh In On uniQure

Institutional investors and hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC acquired a new position in uniQure during the 2nd quarter worth approximately $79,000. Assenagon Asset Management S.A. acquired a new stake in uniQure in the second quarter valued at $815,000. Privium Fund Management B.V. boosted its position in shares of uniQure by 10.6% during the 2nd quarter. Privium Fund Management B.V. now owns 640,416 shares of the biotechnology company’s stock worth $2,869,000 after purchasing an additional 61,501 shares in the last quarter. Doheny Asset Management CA acquired a new stake in shares of uniQure in the second quarter valued at about $1,220,000. Finally, American Century Companies Inc. grew its position in uniQure by 14.6% during the second quarter. American Century Companies Inc. now owns 67,699 shares of the biotechnology company’s stock worth $303,000 after buying an additional 8,642 shares during the period. 78.83% of the stock is owned by hedge funds and other institutional investors.

uniQure Stock Performance

The stock’s fifty day simple moving average is $7.90 and its 200-day simple moving average is $6.68. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The company has a market capitalization of $802.80 million, a PE ratio of -3.32 and a beta of 0.89.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.21. The company had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $2.73 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. On average, research analysts predict that uniQure will post -3.82 earnings per share for the current fiscal year.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.